Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | NTRK1 fusion NTRK1 G595R |
| Therapy | Larotrectinib |
| Indication/Tumor Type | Advanced Solid Tumor |
| Response Type | resistant |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| NTRK1 fusion NTRK1 G595R | Advanced Solid Tumor | resistant | Larotrectinib | FDA contraindicated | Actionable | Vitrakvi (larotrectinib) is contraindicated for solid tumors with an NTRK1 fusion harboring a known NTRK1 resistance mutation, including G595R (FDA.gov). | detail... |
| PubMed Id | Reference Title | Details |
|---|---|---|
| Vitrakvi (larotrectinib) FDA Drug Label | Full reference... |